DAPA-HF Published: ' Stunning Consistent Benefit With Dapagliflozin ' DAPA-HF Published: ' Stunning Consistent Benefit With Dapagliflozin '

Publication of trial reinforces"remarkably consistent" benefits of the SGLT2 inhibitor dapagliflozin in patients with heart failure, with or without diabetes,"bolsters confidence in the conclusions."Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news